CDEK
← All drugs Report issue

diazoxide

Trade name: hyperstat

Small moleculeapproved

Approved

Jan 22, 1973

Diazoxide is a drug which was approved by FDA for the treatment of secondary hyperinsulinemia. The drug exerts its action by binding to SUR1 subunit of ATP-sensitive potassium channel that leads to the channel opening. — NCATS

Clinical trial activity

20 trials · 20 clinical orgs · 7 marketing orgs

Phase 1
5
Phase 2
10
Phase 3
2
Phase 4
4

Earliest trial started Nov 1, 2004 (NCT00151684)

Timeline

1970s

  1. Jan 22, 1973

    Schering — Earliest FDA Approval

  2. Jan 22, 1973

    Schering — NDA Secondary Org

  3. Jan 22, 1973

    Schering — NDA Organization

  4. Jan 22, 1973

    Schering-Plough — NDA Secondary Org

  5. May 28, 1976

    Teva — NDA Secondary Org

2000s

  1. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  2. Dec 20, 2019

    E5 Pharma Inc — Marketing Organization

2020s

  1. Jul 8, 2020

    Novitium Pharma — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewJan 22, 1973

Chemistry & pharmacology

Loading structure…

SMILES

CC1=NC2=CC=C(Cl)C=C2S(=O)(=O)N1
Mol. weight
230.671 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral
Availability
Prescription Only

Oral

Yes

Parenteral

Yes

Topical

No

Sources

Also known as

  • diazossido
  • diazossido
  • diazoxide
  • diazoxide
  • diazoxide
  • diazoxide
  • diazoxide
  • diazoxide
  • diazoxide
  • diazoxide
  • diazoxide
  • diazoxide
  • diazoxide
  • diazoxido
  • diazoxido
  • diazoxidum
  • diazoxidum
  • dizoxide
  • eudemine
  • eudemine
  • eudemine
  • eudimine
  • hyperstat
  • hyperstat
  • hyperstat
  • hyperstat
  • hypertonalum
  • mutabase
  • mutabase
  • proglicem
  • proglycem
  • proglycem
  • sch-6783
  • sch-6783
  • srg-95213
  • srg-95213

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06606327Phase 1Oct 23, 2024Columbia University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT06308107Phase 1Jul 8, 2024Johns Hopkins University
NCT04830982Phase 1Sep 1, 2023Johns Hopkins University
NCT05729282Phase 1Aug 1, 2023Columbia University, University of California, Berkeley
NCT05532020Phase 2Jan 31, 2023Soleno Therapeutics, Inc.
NCT03685773Phase 2Nov 30, 2018Yeshiva University
NCT03608163Phase 4Aug 10, 2018National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Yeshiva University
NCT03540758Phase 2Aug 1, 2018National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Yeshiva University
NCT03566511Phase 2Jun 12, 2018National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Yeshiva University
NCT02779257Phase 4Apr 1, 2016Novartis, University of Maryland
NCT02049385Phase 1/Phase 2 (Phase 2)Jan 3, 2014National Institute of Mental Health (NIMH)
NCT01488136Phase 4Jan 1, 2012Juvenile Diabetes Research Foundation, University of Dundee
NCT01028846Phase 2May 1, 2011Yeshiva University
NCT00994149Phase 2/Phase 3 (Phase 3)Oct 1, 2009University of Saskatchewan
NCT00631033Phase 2Jul 1, 2008Rijnstate Hospital
NCT00892073Phase 2May 1, 2006University of Toronto
NCT00306683Phase 3Apr 1, 2006University of Paris
NCT00683774N/ANov 1, 2005National Institutes of Health (NIH), Virginia Commonwealth University
NCT00131755Phase 4Feb 1, 2005Grill, Valdemar, M.D., Norwegian University of Science and Technology
NCT00151684Phase 2Nov 1, 2004Rijnstate Hospital, University of Twente
Showing 20 of 20 trials
Page 1 / 1

Organizations

Research & Development (20)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Yeshiva UniversityAcademic/Hospital5522011
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government4032018
National Institutes of Health (NIH)Government4032005
Columbia UniversityAcademic/Hospital2212023
Johns Hopkins UniversityAcademic/Hospital2212023
Rijnstate HospitalAcademic/Hospital2212004
Grill, Valdemar, M.D.Academic/Hospital1112005
Juvenile Diabetes Research FoundationAcademic/Hospital1012012
National Institute of Mental Health (NIMH)Government1112014
Norwegian University of Science and TechnologyAcademic/Hospital1012005
NovartisFor profit1012016
Soleno Therapeutics, Inc.For profit1112023
University of California, BerkeleyAcademic/Hospital1012023
University of DundeeAcademic/Hospital1112012
University of MarylandAcademic/Hospital1112016
University of ParisAcademic/Hospital1112006
University of SaskatchewanAcademic/Hospital1112009
University of TorontoAcademic/Hospital1112006
University of TwenteAcademic/Hospital1012004
Virginia Commonwealth UniversityAcademic/Hospital1112005
20 organizations
Page 1 / 1

Marketing (8)

OrganizationOrg typeRelationshipDate
AbraxisFor profitMKTG—
Athenex, Inc.For profitMKTG—
E5 Pharma IncFor profitMKTGDec 20, 2019
Novitium PharmaFor profitMKTGJul 8, 2020
ScheringFor profitNDA2Jan 22, 1973
ScheringFor profitNDAJan 22, 1973
Schering-PloughFor profitNDA2Jan 22, 1973
TevaFor profitNDA2May 28, 1976